Accordingly, we aimed to investigate and explore the possible role of TUG-1/miR-186/SIRT3, PPAR-1α and HIF-1α axis in TMX resistance and TMX sensitive BC patients and to correlate the aforementioned axis with tumor progression, different clinical presentations, anthropometric parameters and other metabolic biomarkers in BC. Here, TUG1 is linked to breast cancer.